EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy

Eric V Li iD, Edward M Schaeffer iD, Sai Kaushik Shankar Ramesh Kumar, Ruoji Zhou, Ximing J Yang, Margarita Mana-Ay, Mariavittoria Vescovo, Austin Ho, Mary Kate Keeter, James Carr, David Casalino, Masha Kocherginsky und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025-06 · 52 (7) · 2335-2342

DOI: 10.1007/s00259-025-07133-1 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 10.02.2025. Verfasst von Eric V Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Feinberg School of Medicine, Department of Urology, Northwestern University, 676 N. St. Clair St., Suite 2300, Chicago, IL, 60611, USA. eric.li1@nort…. Hauptthemen laut MEDLINE: Lysine, Positron-Emission Tomography, Prostatectomy, Prostatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: NCI NIH HHS, Lantheus Medical Imaging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: PSMA PET offers the potential for improved local staging prior to radical prostatectomy (RP). We evaluated PSMA PET versus mpMRI for local and nodal staging for patients with localized NCCN high or very high risk prostate cancer undergoing RP. METHODS: A prospective single center pilot study was conducted from 9/2018 to 6/2022. Patients underwent both mpMRI and 18F-DCFPyL PSMA PET with limited MRI sequences, followed by RP with pelvic lymphadenectomy. Patient and side-specific performance of mpMRI and PSMA PET were compared to RP histopathological standard of truth for extraprostatic extension (EPE), seminal vesicle invasion (SVI), and lymph node involvement (LNI). RESULTS: At RP, 79% (38/48) had EPE, 31% had SVI, and 31% had LNI. At the patient level for EPE, PSMA PET had similar sensitivity (65.8% vs. 84.2%, respectively, P = 0.07) but higher specificity (80% vs. 40%, P = 0.045) compared to mpMRI, respectively. For SVI, PSMA PET had lower sensitivity (62.5% vs. 87.5%, P = 0.046) and similar specificity (87.5% vs. 90.6%, P = 0.56). For side-specific LNI, PSMA PET had higher sensitivity (50% vs. 25%, P = 0.03) and similar specificity (96.1% vs. 94.7%, P = 0.71) compared to mpMRI. CONCLUSION: PSMA PET offers higher specificity for EPE and higher sensitivity for LNI compared to mpMRI. PSMA PET may improve overall surgical planning, and may be combined with diagnostic mpMRI and clinicopathological variables through nomograms to further predict EPE, SVI, or LNI. CLINICAL TRIAL REGISTRATION: NCT03392181 https://clinicaltrials.gov/study/NCT03392181 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysinePositron-Emission TomographyProstatectomyProstatic NeoplasmsUreaAgedHumansMaleMiddle AgedMultiparametric Magnetic Resonance ImagingNeoplasm StagingPilot ProjectsProspective Studies

Stichwörter der Autor:innen

CancerPSMAPosition-emission tomographyProstate cancerStaging

Substanzen

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acidLysineUrea

Autor:innen und Institutionen

  • Feinberg School of Medicine, Department of Urology, Northwestern University, 676 N. St. Clair St., Suite 2300, Chicago, IL, 60611, USA. eric.li1@northwestern.edu.
  • Feinberg School of Medicine, Department of Urology, Northwestern University, 676 N. St. Clair St., Suite 2300, Chicago, IL, 60611, USA.
  • Feinberg School of Medicine, Department of Preventative Medicine, Northwestern University, Chicago, IL, 60611, United States of America.
  • Department of Pathology, University of California in Los Angeles, Los Angeles, CA, 90095, United States of America.
  • Feinberg School of Medicine, Department of Pathology, Northwestern University, Chicago, IL, 60611, United States of America.
  • Feinberg School of Medicine, Department of Radiology, Northwestern University, Chicago, IL, 60611, United States of America.

ORCID-Profile: Eric V Li, Edward M Schaeffer, Hiten D Patel, Ashley E Ross

Förderung

  • NCI NIH HHS
  • Lantheus Medical Imaging

Zitieren

APA

Li, E. V., Schaeffer, E. M., Ramesh Kumar, S. K. S., Zhou, R., Yang, X. J., Mana-Ay, M., Vescovo, M., Ho, A., Keeter, M. K., Carr, J., Casalino, D., Kocherginsky, M., Patel, H. D., Ross, A. E., & Savas, H. (2025). Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 52(7), 2335-2342. https://doi.org/10.1007/s00259-025-07133-1

Vancouver

Li EV, Schaeffer EM, Ramesh Kumar SKS, Zhou R, Yang XJ, Mana-Ay M, et al. Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(7):2335-2342. doi:10.1007/s00259-025-07133-1

BibTeX
@article{Li2025,
  author = {Li, Eric V and Schaeffer, Edward M and Ramesh Kumar, Sai Kaushik Shankar and Zhou, Ruoji and Yang, Ximing J and Mana-Ay, Margarita and Vescovo, Mariavittoria and Ho, Austin and Keeter, Mary Kate and Carr, James and Casalino, David and Kocherginsky, Masha and Patel, Hiten D and Ross, Ashley E and Savas, Hatice},
  title = {Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {7},
  pages = {2335--2342},
  doi = {10.1007/s00259-025-07133-1}
}
Kostenlos starten →